Publications and Innovation
May 20, 2020 - Sera Prognostics, Inc., The Pregnancy Company® announced the publication of positive data in a large, independent, contemporary prospective U.S. clinical cohort study, TREETOP (NCT02787213), in the American Journal of Obstetrics & Gynecology Maternal Fetal Medicine.
January 2020 – Abstract of data to determine the performance of a previously validated, clinically available, proteomic preterm birth (PTB) predictor in an independent cohort distinct from the tone in which it was developed, that will be presented at the Society for Maternal-Fetal Medicine’s 2020 Annual Meeting.
January 2020 – Abstract of data to evaluate the predictive performance of established preterm birth biomarkers when combined with additional clinical and proteomic markers that will be presented at the Society for Maternal-Fetal Medicine’s 2020 Annual Meeting.
December 2019 – Published in the peer-reviewed journal, Obstetrics & Gynecology, the authors explain the importance of following best practices for development of omics tests, identifying examples of biomarker research that reports falsely elevated performance through selective omission of subsets of patients from the data analysis.
June 2017 – Sera's recent analytical study, “Analytical Validation of Protein Biomarkers for Risk of Spontaneous Preterm Birth” has been published in the June issue of Clinical Mass Spectrometry. The study details a rigorous analytical validation of Sera’s liquid chromatography/mass spectrometry (LC/MS) platform for sensitive later-generation Agilent mass spectrometers.
December 2016 – Published in the American Journal of Perinatology Reports, the authors of this article concluded that “the use of a prognostic test for reducing spontaneous preterm birth is a dominant strategy that could reduce costs and improve outcomes.” Other findings from the report state that preterm birth risk testing and intervention could result in: